Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
LaggingWe are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Our pharmaceutical business features NGENLA® (somatrogon-ghla), also referred to as Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. We have partnered with Pfizer Inc. (“Pfizer”) for further development and commercialization of Somatrogon (hGH-CTP).
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Jun 2026 · $187.4MThe company’s own SEC segment disclosure.
- Service$74.5M40%
- Intellectual Property And Other$46.1M25%
- Transfer Of Intellectual Property And Other$46.1M25%
- Rayaldee$14.3M8%
- Royalty$6.4M3%
OPKO Health, Inc. (OPK) reported revenue of $124M in Q1 2026 (quarter ended Mar 31, 2026), down 17% from the same quarter a year earlier. That came with a gross margin of 37% and net loss of $55M. For the full year FY2025, revenue was $607M (−15% year on year) and net income −$226M. Its largest product in Jun 2026 was Service at $75M, 40% of the disclosed total, ahead of Intellectual Property And Other at 25%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #16 of 17 by Smart Score